Semaglutidepeptide:
Sequence:
MolecularFor
His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Le u-Glu-Gly-Gln-Ala-Ala-Lys(PEG2-PEG2γ-Glu-17-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-L eu-Val-Arg-Gly-Arg-Gly
mula: C187H291N45O59
MolecularWe
ight: 4113.64g/mol
PubChemCI
D: 56843331
CASNumber:910463-68-2
Synonyms: Ozempic;Rybelsus;NN9535;Wegovy
Asasuper“weightlossmagicdrug”,Semaglutidepeptidegettingmoreand morepopularWhentyping"weightlossdrug"onthemajorsocialplatforms, whatcomesintoviewisthepursuitof"thinness"and"beauty"bymanypeopl eTheymaysharehowtobuyweightlossdrugonlineortheweightlossdrug useeffects.Oneofthemostfrequentlymentionedweightlossdrugsisundo ubtedlysemaglutide.
SemaglutidepowderistheactiveingredientoffamousbrandOzempic;Rybelsu s;NN9535;Wegovy.Semaglutidedevelopmenthasgonethroughalongandc omplexprocess,fromSemaglutidepowdersynthesis,Semaglutidefinishedvials manufacturing,andSemaglutideuse,effects,mechanismofaction,storageetc Herelet’sviewthehistoryofSemaglutideanditsrelativeproducts.
【2008】
SemaglutidestartitsphaseIIclinicaltrialstudyingandachievedgoodresults.
【2012】
AstheR&DcompanyofSemaglutide,NovoNordiskdevelopSemaglutideasa potentialdiabetestherapy
【2016-2017】
Researchersstartclinicaltrialsthatevaluatesemaglutideefficacyinbloodsugar controlandcardiovascularriskreductionareconducted.
【Oct.2017】
SemaglutideapprovedbyFADAdvisoryCommitteeforthetreatmentofdiabet es
【Dec.2017】
SemaglutidemarkedasbrandnameofOzempic,andapprovedbyFDAfordia betesmanagementuseinUSA
【Jan2018】
SemaglutidebrandOzempicisapproveduseinCanada
【Feb.2018】
OzempicasoneofthefamousbrandofSemaglutide,approvedtobeusedin EuropeanUnion,andinthesameyear,Japanapprovesformedicaluse.
【Aug2019】
OzempicisapprovedformedicalusebyAustraliangovernment.Inthesamey ear,semaglutideoralbrandRybelsusapprovedbyFDAthatusefordiabetestr eatmentintheUSA
【Apr.2020】
Rybelsus(brandnameofsemaglutideoralform)obtainapprovalformedicalu seinEuropeanUnion
【Jun.2021】
Wegovy,thehigherdosageversionofSemaglutide,isapprovedbyFDAforlon g-termweightlossmanagementinadults
【Nov.2021】
TheCHMPoftheEuropeanMedicinesAgencyrecommendsmarketingauthoriz ationforWegovy(Semaglutidebrandname)
【Jan.2022】
WegovyisapprovedformedicaluseintheEuropeanUnioin
ThelabelforSemaglutideoralversionRybelsusisupdatedtoreflectitsuseas afirst-linetreatmentforadultswithtype2diabetes
ThisreviewofSemaglutidebackgroundoutlinesthesignificantmilestonesinth edevelopmentofsemaglutide,fromitsinitialstagesofresearchandclinicaltri alstoitssubsequentapprovalsforthemanagementofdiabetes,weightloss,a ndreductionofcardiovascularrisk.Thesemilestonesattesttotheeffectiveness ofsemaglutidepowderasatreatmentforweightlossandtype2diabetes.O ngoingresearchendeavorsfocusonelucidatingsemaglutide'smechanismsofa ction,assessingitssafetyprofile,andevaluatingitsefficacy.Theseinvestigation sextendtoitsimpactonmetabolichealthandpotentialapplicationsbeyondd iabetesandobesity.Researchersseekingtoprocuresemaglutidepowderforth eirstudieswilldiscoverthatpurchasingitonlineisacost-efficientoption.How ever,amidsttheplethoraofsemaglutidepowderavailableforsaleonline,ident ifyingareputablemanufacturerposesachallenge.
Semaglutideisapeptidethatbelongstoaclassofmedicationsknownasgluc agon-likepeptide-1receptoragonists,orGLP-1RAs.ItmimicstheGLP-1horm one,worksbyincreasinginsulinrelease,loweringtheamountofglucagonrele ased,delayinggastricemptyingandreducingappetite.
Semaglutideisapprovedasaprescriptionmedicineusedforweightlossinspe cificpatients,andtolowerbloodsugarlevelsandreducetheriskofmajorcar diovasculareventssuchasheartattackorstrokeintypetwodiabetespatients.
Foryoursafety,pleasebuyanduseSemaglutidewithcaution
Withdifferentstrengthversionsandfordifferentpurposes,Semaglutideisappr ovedunder3differentbrandnames,includingWegovy,Ozempic,andRybelsus.
Let’stakealookatthedifferencesandsimilaritiesbetweenthesedifferentS emaglutidebrandnames.
ThesimilaritiesofWegovy,Ozempic,Rybelsus
TheyallhavethesameactiveingredientofSemaglutidepowder;
TheyallapprovedbyFDAusefordifferentpurpose;
Theyneedtobuywithprescription;
ThedifferencebetweenWegovy,Ozempic,Rybelsus
RybelsusistheoraltabletversionofSemaglutide,itisapprovedusetolower bloodsugarlevelsfortypetwodiabeticpatientsalongwithdietandexercise, andistakenasatabletonceaday.Thestrengthhas3mgtablet,7mgtablet and14mgtablet.AsoralversionofSemalgutide,itismoreconvenienttouse thantheinjectionversion.
WegovyistheinjectionversionofSemaglutide,itisapproveduseforweight managementforaspecificgroupofpatientsandisgivenasasubcutaneousi njectionweeklyThestrengthhas025or05mgdosepen,1mgdosepenand 2mgdosepen.
OzempicistheinjectionversionofSemaglutide,itisapproveduseforlowerb loodsugarlevelsfortypetwodiabeticpatients,alongwithdietandexercise.It isalsousedfordiabeticpatientswhoalreadyhavecardiovasculardisease,to helplowertheriskofmajorcardiovasculareventssuchasheartattackorstrok eOzempicisgivenasasubcutaneousinjectionweeklyThestrengthhas025 mgdosepen,0.5mgdosepen,1mgdosepen,1.7mgdosepenand2.4mgdo sepen.
Semaglutidebelongstoaclassofcompoundscalledglucagon-likeprotein-1(GLP-1) receptoragonists,whichhavebeenapprovedintheUnitedStatessince2005for managingbloodsugarlevelsintype2diabetes.Semaglutideisalsobelievedtobea powefulmedicineforweightmanagementpurpose.Herelet’stakeadeeplookat semaglutidemechanismandhowissemaglutideworking.
Semaglutideisapeptidesimilartothehormoneglucagon-likepeptide-1(GLP-1), modifiedwithasidechain.Glucagon-likepeptide-1(GLP-1)isaphysiological hormonethathasmultipleactionsonglucose,mediatedbytheGLP-1receptorsIt mimicstheGLP-1hormone,releasedinthegutinresponsetoeating.Oneroleof
GLP-1istopromptthebodytoproducemoreinsulin,whichreducesbloodsugar (glucose).ThemethodofSemaglutideworkforweightlossare:
BoostingSatietyandControllingAppetite:GLP-1receptors,abundantinbrain regionsgoverningappetite,areactivatedbySemaglutide.Thisactivationincreases thesensationoffullnessanddecreaseshunger,promotingmindfuleatingand reducingcalorieintake,crucialforeffectiveweightmanagement.
SlowingDigestion:Semaglutidenotonlysuppressesappetitebutalsodelays gastricemptying,prolongingthefeelingoffullnesspost-meal.Thisslowscravings andaidsinresistingovereating.
RegulatingPleasureResponse:Semaglutideimpactsthebrain'srewardpathways linkedtofoodenjoyment.Bytargetingthesepathways,Semaglutidediminishesthe allureofhigh-caloriefoods,facilitatingadherencetodietarygoals.
Revvinguprestingmetabolismandburningfat
Semaglutidedoesnotjustregulateappetite,butalsoorchestratesmetabolic changesimpactingenergyexpenditureandfatutilization.Semaglutidehasbeen demonstratedtoelevatebasalmetabolicrate,itsupportingweightmanagement evennoexercise.Meantime,anotheramazingaspectofSemaglutideisits promotionoffatbreakdownByboostinglipolysis,semaglutidefacilitatesthe utilizationofstorredenergy,aidinginweightlosseffeorts.
ItcanbesaidthatSemaglutideisaproductthatallowsyoutoloseweightwhilelying down.Ifyouarefacingtheproblemoflosingweight,youmightaswelltrytobuy
semaglutideforatryBesuretobuysemaglutidefromaregularsource,buy semaglutideonlineisnotabadchoice,theimportantistofindareliable semaglutidemanufacturer.
Semaglutideprovideseveralbenefitstopeoplewhoseekingtoloseweightand peoplewithtype2diabetes.Herearethebenefitslistrelatetotheuseof semaglutidepowder.
BothSemaglutidebrandnameofOzempicandRybelsushavereceivedFDAapproval fortreatingtype2diabetes.TheactiveingredientSemaglutidepowder,operatesby mimickingthefunctionoftheGLP-1hormone,whichaidsinregulatingbloodsugar levels,enhancinginsulinsecretion,andreducingappetiteBelowareseveralbenefits thatpatientswithtype2diabetescanexperiencewhenusingsemaglutidepowder:
ImprovedBloodSugarManagement:Semaglutideassistsincontrollingblood sugarlevelsbyincreasinginsulinsecretionanddecreasingglucagonproduction, leadingtobetterbloodsugarregulationandalowerriskofhyperglycemia(high bloodsugar).
ReducedHbA1cLevels:Studieshavedemonstratedthatusesemaglutidecanlower HbA1clevels,anindicatorofaveragebloodsugarlevelsovertime,thusreducingthe riskofdiabetes-relatedcomplications.
CardiovascularAdvantages:Researchsuggeststhatsemaglutideusemaydecrease thelikelihoodofmajoradversecardiovascularevents,suchasheartattacks,strokes, andcardiovascular-relatedmortality,inindividualswithdiabetesandpre-existing cardiovascularconditions.
WeightManagement:Manypeoplewithtype2diabetesstrugglewithweight controlPeptideSemaglutidenotonlyhelpsregulatebloodsugarlevelsbutalso promotesweightloss,whichisbeneficialforoverallhealthanddiabetes management.
SemaglutideforWeightLoss
Semaglutide,marketedasWegovyforweightloss,holdsexclusiveFDAapprovalfor thispurpose.Accordingtoa68-weekstudy,adultsexperiencedanaverageweight lossof35poundsor15%oftheiroverallbodyweightwhileusingSemaglutide powderIfyou'vebeengrapplingwithobesityorexcessweightandhavenot achievedsuccesswithlifestylechangesalone,Semaglutidemayoffertheadditional supportyouneed.Additionally,buyingSemaglutidepowderinbulkcanresultin favorablepricing.Herearesomebenefitsofsemaglutideforweightloss:
SubstantialWeightReduction:Semaglutidehasdemonstratedsignificantand sustainedweightlossinindividualswithobesityorexcessweight,whichcan positivelyimpactoverallhealthandwell-being.
AppetiteControl:UseSemaglutidetoslowgastricemptyingandincreasesfeelings offullness,aidinginappetitesuppressionandfoodintakeregulation
EnhancedMetabolicHealth:Weightlossachievedwithsemaglutidepowdercan leadtoimprovementsinmetabolicmarkerssuchasreducedbloodpressure, improvedcholesterollevels,andenhancedinsulinsensitivity.
ReducedRiskofWeight-RelatedConditions:Sheddingexcessweightcandecrease theriskofobesity-relatedconditions,includingtype2diabetes,cardiovascular disease,andcertaincancers.
ImprovedQualityofLifeandincreasedself-confidence:Successfulweightloss canleadtoenhancedself-esteem,increasedmobility,andanoverallbetterqualityof life
It'simportanttonotethattheeffectsofsemaglutideareoptimizedwhencombined withabalanceddiet,regularphysicalactivity,andongoingmedicalsupervision. Potentialadverseeffectsandindividualresponses,aswithanymedication,shouldbe assessedanddiscussedwithahealthcareprofessional"
TakingSemaglutideisoftenassociatedwithsomesideeffects,gastrointestinalissues arethemostcommoncomplaintamongpeoplejuststartingsemaglutide.Butthe sideeffectsofsemaglutidepowderaretypicallymild,especiallywhencomparedto thecomplicationsassociatedwithoverweightandobesity.
Herearetheprimarysideeffectsofpeopletakingsemaglutideforweightlossmay experience:
Dizziness:takingSemaglutidemaycausedizziness,andthedegreeofdizziness variesfrompersontoperson.
Fatigue:mayfeeltiredaftertakingSemaglutide,whichmayberelievedbyrest
Gastrointestinalissues:suchasdiarrhea,constipationandgassiness
Headache
Stomachissues:includingnausea,vomiting,painordistension(bloat)
Semaglutide,whenprescribedandmonitoredbyhealthcareprofessionals,is generallyregardedassafe.WhileenjoyingthemanybenefitsofSemaglutide,howto
reducethesideeffectsofSemaglutide?Youmaybeabletoreducethesideeffects bybeginningonalowerdoseandthenslowlyincreasingtheamountyoutake.
DonotshareyourSemaglutideinjectionwithotherpeople,eveniftheneedlehas beenchanged.Youmaygiveotherpeopleaseriousinfection,orgetaserious infectionfromthem
Theshortageandhighcostofsemaglutidehavepromptedanincreasingnumberof individualstobuytheirSemaglutidepowderonlinethatdrawingattentionfromthe FDA.TheFDAhasexpressedconcernsregardingthesafetyofdifferentsaltformsof semaglutidepowderavailableonlineHowever,despitethesewarnings,individuals likeCarlosAlvarezcontinuetoseekoutaffordablesemaglutidepeptideonline,often relyingonlabtestreportsandqualityguarantees.Asthispracticegainstraction,new onlinecommunitieshaveemergedwhereusersexchangeexperiencesonusing semaglutidepowderandlocatingreputablepeptidesuppliers.Beforepurchasing semaglutidepowder,Phcokerstandsoutasoneofthepeptidemanufacturersyou shouldconsider.
Semaglutide,asyntheticpeptide,wasinitiallydevelopedin2012bytheglobal pharmaceuticalcompanyNovoNordisk.Despiteitsbenefitsinbloodsugarcontrol andweightmanagement,thecostofsemaglutidebasedmedicationsmaypresent economichurdlesforcertainindividualsandhealthcaresystems.Theongoing expenseoftreatmentcanimpacthealthcarebudgetsandpatientout-of-pocket expenditures.Moreover,insurancecoverageforsemaglutidemedicationsvaries, withsomeinsurancecompaniesscrutinizinganddenyingcoverageforpatients lackingsufficientevidencetosupportadiabetesdiagnosis(citingoff-labelusefor weightloss).
Thehighsemaglutidecosthassparkedconversationsaboutaccessibility,andthe increasingpopularityofsemaglutideforweightlossanddiabetesmanagementhas resultedinasurgeindemand.Consequently,morequalifiedpeptidemanufacturers areproducingSemaglutidepowderintheirindependentlabs.
SemaglutideisavailablefromPhcokerinbothrawpowderandlyophilizedpowder forms.
SemaglutideRawPowder:Semaglutidepowderactastheactiveingredientpowder foundinsemaglutide-basedmedicationssuchasOzempic,Wegovy,andRybelsus.It isfrequentlyutilizedforresearchpurposesbyscientistsandresearchers.Researchers employsemaglutidepowdertodevelopsolutionsforlaboratoryexperimentsorto formulatevariousadministrationmethods,includinginjectionsororaltablets.
SemaglutideInjectionForm(Semagluitde5mg,10mg):Themostprevalentform ofsemaglutideavailableforreconstitutionisalyophilizedpowder,whichisa freeze-driedformofthepeptide.Thispowderismixedwithasuitablediluent,such asbacteriostaticwaterorsterilewater,tocreateaninjectablesolution. Reconstitutioninstructionsmayvarydependingonthespecificproductand Semaglutidepeptidemanufacturer,soitisimperativetocarefullyadheretothe providedguidelines.
Weightmanagementisalong-terminvestment.Withinsurancecompaniesno longercoveringit,peoplewhouseSemaglutidearespecificallylookingtobuy
SemaglutideonlineorfindalternativestoSemaglutideHerearesomepopular
Semaglutidealternatives:
Tirzepatide:TirzepatideisanovelmedicationthatisFDAapprovedforthe treatmentoftype2diabetesmellitus.Givenitspotentweightlossproperties, tirzepatidebeusedoff-labelforobesitytreatmentItworksasadualGLP-1agonist andGIPagonisttomaximizesimilarbenefitsthatareseenwithGLP-1medications suchassemaglutide.
Retatrutide:Retatrutideisaninvestigationaltreatmentforobesitythatisatriple hormonereceptoragonistfromEliLillyRetatrutideisagastricinhibitory polypeptide(GIP),glucagon-likepeptide-1(GLP-1)andglucagonreceptor agonist,worksinthetreatmentofobesitybytargetingthreedifferenthunger regulatinghormones.
Cagrilintide:Cagrilintideisalong-actingamylinanalogueforthetreatmentof obesity.Amylinisco-locatedwithinsulininsecretorygranulesandco-secretedwith insulinbypancreaticbetacellsinresponsetofoodintake.
Cansemaglutidebecompounded?
OzempicandWegovyarebothontheFDA'sDrugShortageslistasofMay2023.
Whenadrugisinlowsupply,compoundersmaybeabletomanufacturea compoundedversionofthatdrugiftheymeetspecificrequirements
HowmuchweightcanyouloseonSemaglutideinjectionin3months?
OnestudyfoundpeoplewhoreceivedweeklySemaglutideinjectionslostanaverage ofabout15poundsafterthreemonthsandabout27poundsaftersixmonths,which translatesintoabouta5-poundweightlosspermonth
DoesSemaglutidepeptidepowdergetridofbellyfat?
BymimickingtheGLP-1hormone,slowingthedigestiveprocess,andstimulatingfat oxidation,Semaglutidecanhelppatientsloselargeamountsofbellyfat. HowfastwillIloseweightonSemaglutideinjection?
Accordingtoclinicalstudies,mostpeoplestarttoseenoticeableweightlossafter about4to12weeksofregularSemaglutideuse.However,individualresultsvary
basedonstartingweight,diet,exercise,andadherencetothemedicationregimen
CanIlose20poundsinamonthwithSemaglutidepeptide?
Sowitheachhigherdose,weshouldcontinuetoseemoreandmoreweightloss.
Rememberthatthisistheaverageweightloss.Wedidhavepatientswholosta moderateamountbutwealsohadpatientslosingover15poundsandevenover20 poundsinthefirstmonth!
WhoCannottakeSemaglutide?
AvoidSemaglutideifyouhave:Historyofmedullarythyroidcancer.Historyof gallbladderdiseaseHistoryofpancreatitisAndifyouarepregnantorgetreadyfor pregnancy,pleasedonotuseSemaglutide.
Whycan’tyoudrinkonSemaglutide?
Semaglutideisn’tknowntointeractwithalcohol.However,thismedicationand alcoholbothloweryourbloodsugar,sodrinkingalcoholduringyourSemaglutide weightlosstreatmentmaycauseseverehypoglycemia.
HowlongshouldIstayonSemaglutide?
MostpatientswhohavebeenprescribedSemaglutideinjectionsforweightlosswill havetheprescriptionfor68weeksaslongastheycancontinuetakingthe medicationsafelywithoutexperiencingsignificantsideeffects.
WhathappenswhenyoustoptakingSemaglutide?
AsyoutransitionoffSemaglutide,you’llslowlyandgraduallybegintoregainyour appetiteandfoodcravings.You’llhavetimetogetusedtothemwhileestablishing ahealthydietandgoodexerciseroutine.Thisshouldstopyoufromregainingweight whenyoustopsemaglutidecompletely.
SemaglutideVsTirzepatide:whatarethedifference?
Weightlosswithsemaglutiderangedfrom6to10kg(13.2to22lb).Withtirzepatide, weightlossrangedfrom7to13kg(15.4to28.6lb).Tirzepatidemayhaveabetter effecttohelplowerbloodsugarandleadtoweightlossinsomepatients,butmaybe associatedwithmorestomachsideeffectsathigherdoses.
ReferencesCitations:
[1]WildingJPH,BatterhamRL,CalannaS,DaviesM,VanGaalLF,LingvayI,McGowan
BM,RosenstockJ,TranMTD,WaddenTA,WhartonS,YokoteK,ZeuthenN,Kushner RF;STEP1StudyGroup.”Once-WeeklySemaglutideinAdultswithOverweightor Obesity.”NEnglJMed.2021Mar18;384(11):989-1002.doi:
10.1056/NEJMoa2032183.Epub2021Feb10.PMID:33567185 [2]RubinoDM,GreenwayFL,KhalidU,O’NeilPM,RosenstockJ,SørrigR,Wadden TA,WizertA,GarveyWT;STEP8Investigators.”EffectofWeeklySubcutaneous SemaglutidevsDailyLiraglutideonBodyWeightinAdultsWithOverweightor ObesityWithoutDiabetes:TheSTEP8RandomizedClinicalTrial.”JAMA.2022Jan
11;327(2):138-150.doi:10.1001/jama.2021.23619.PMID:35015037 [3]FríasJP,DaviesMJ,RosenstockJ,PérezManghiFC,FernándezLandóL,Bergman BK,LiuB,CuiX,BrownK;SURPASS-2Investigators.”TirzepatideversusSemaglutide OnceWeeklyinPatientswithType2Diabetes.”NEnglJMed.2021Aug
5;385(6):503-515.doi:10.1056/NEJMoa2107519.Epub2021Jun25.PMID:34170647 [4]WeghuberD,BarrettT,Barrientos-PérezM,GiesI,HesseD,JeppesenOK,KellyAS, MastrandreaLD,SørrigR,ArslanianS;STEPTEENSInvestigators.”Once-Weekly SemaglutideinAdolescentswithObesity.”NEnglJMed.2022Dec
PeptideGMPManufacturers
www.phcoker.com
15;387(24):2245-2257doi:101056/NEJMoa2208601Epub2022Nov2PMID:
36322838
[5]SmitsMM,VanRaalteDH.”SafetyofSemaglutide.”FrontEndocrinol(Lausanne). 2021Jul7;12:645563.doi:10.3389/fendo.2021.645563.eCollection2021.PMID:
34305810
[6]RubinoD,AbrahamssonN,DaviesM,HesseD,GreenwayFL,JensenC,LingvayI, MosenzonO,RosenstockJ,RubioMA,RudofskyG,TadayonS,WaddenTA,DickerD; STEP4Investigators.”EffectofContinuedWeeklySubcutaneousSemaglutidevs PlaceboonWeightLossMaintenanceinAdultsWithOverweightorObesity:The STEP4RandomizedClinicalTrial.”JAMA.2021Apr13;325(14):1414-1425.doi: 10.1001/jama.2021.3224.PMID:33755728
[7]O’NeilPM,BirkenfeldAL,McGowanB,MosenzonO,PedersenSD,WhartonS, CarsonCG,JepsenCH,KabischM,WildingJPH”Efficacyandsafetyofsemaglutide comparedwithliraglutideandplaceboforweightlossinpatientswithobesity:a randomised,double-blind,placeboandactivecontrolled,dose-ranging,phase2 trial.”Lancet.2018Aug25;392(10148):637-649.doi:
PeptideGMPManufacturers www.phcoker.com
101016/S0140-6736(18)31773-2Epub2018Aug16PMID:30122305
[8]ChaoAM,TronieriJS,AmaroA,WaddenTA.”Semaglutideforthetreatmentof obesity.”TrendsCardiovascMed.2023Apr;33(3):159-166.doi:
10.1016/j.tcm.2021.12.008.Epub2021Dec21.PMID:34942372
[9]SinghG,KrauthamerM,Bjalme-EvansM.”Wegovy(semaglutide):anewweight lossdrugforchronicweightmanagement.”JInvestigMed.2022Jan;70(1):5-13.doi:
10.1136/jim-2021-001952.Epub2021Oct27.PMID:34706925
[10]WaddenTA,BaileyTS,BillingsLK,DaviesM,FriasJP,KorolevaA,LingvayI, O’NeilPM,RubinoDM,SkovgaardD,WallensteinSOR,GarveyWT;STEP3 Investigators.”EffectofSubcutaneousSemaglutidevsPlaceboasanAdjunctto IntensiveBehavioralTherapyonBodyWeightinAdultsWithOverweightorObesity: TheSTEP3RandomizedClinicalTrial.”JAMA.2021Apr13;325(14):1403-1413.doi: 101001/jama20211831PMID:33625476
[11]ChristouGA,KatsikiN,BlundellJ,FruhbeckG,KiortsisDN.”Semaglutideasa promisingantiobesitydrug.”ObesRev.2019Jun;20(6):805-815.doi:
101111/obr12839Epub2019Feb15PMID:30768766
[12]MeierJJ.”EfficacyofSemaglutideinaSubcutaneousandanOral Formulation.”FrontEndocrinol(Lausanne).2021Jun25;12:645617.doi:
10.3389/fendo.2021.645617.eCollection2021.PMID:34248838
[13]GarveyWT,BatterhamRL,BhattaM,BuscemiS,ChristensenLN,FriasJP,JódarE, KandlerK,RigasG,WaddenTA,WhartonS;STEP5StudyGroup.”Two-yeareffectsof semaglutideinadultswithoverweightorobesity:theSTEP5trial.”NatMed.2022
Oct;28(10):2083-2091.doi:10.1038/s41591-022-02026-4.Epub2022Oct10.PMID:
36216945
[14]HusainM,BirkenfeldAL,DonsmarkM,DunganK,EliaschewitzFG,FrancoDR, JeppesenOK,LingvayI,MosenzonO,PedersenSD,TackCJ,ThomsenM,VilsbøllT, WarrenML,BainSC;PIONEER6Investigators.”OralSemaglutideandCardiovascular OutcomesinPatientswithType2Diabetes”NEnglJMed2019Aug
29;381(9):841-851.doi:10.1056/NEJMoa1901118.Epub2019Jun11.PMID:
31185157
[15]WildingJPH,BatterhamRL,DaviesM,VanGaalLF,KandlerK,KonakliK,LingvayI, McGowanBM,OralTK,RosenstockJ,WaddenTA,WhartonS,YokoteK,KushnerRF; STEP1StudyGroup.”Weightregainandcardiometaboliceffectsafterwithdrawalof semaglutide:TheSTEP1trialextension.”DiabetesObesMetab.2022
Aug;24(8):1553-1564.doi:10.1111/dom.14725.Epub2022May19.PMID:35441470